DTX PHARMA

Pharmaceutical preparations, namely, oligonucleotide compounds; oligonucleotide compounds for the treatment of genetic diseases; oligonucleotide delivery agents in the form of intravenous infusion or injection, suspension or sterile powder for the treatment of genetic diseases; pharmaceutical preparations for the treatment of genetic diseases; therapeutic preparations using RNA to treat ocular, neuromuscular and central nervous system (CNS) diseases; fatty acid-based oligonucleotide delivery agents in the form of intravenous infusion or injection, suspension or sterile powder for the treatment of genetic diseases

Pharmaceutical research and development of oligonucleotide compounds; scientific research and product development in the field of oligonucleotide compounds and drug discovery; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in therapeutic discovery and development; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in the treatment of genetic diseases; Pharmaceutical research and development of therapeutic preparations using RNA to treat ocular, neuromuscular and central nervous system (CNS) diseases